Vindesine Sulfate

Phase 3Small molecule

UUniversity Hospital Muenster

Vindesine Sulfate is one of 48 small molecule programs targeting Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeukemiaActive, not recruiting

LeukemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Leukemia

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Phase 3

31 2

Fludara

Sanofi

Phase 3

22 3

Neoral

Novartis

Phase 3

9 4

Decadron

AAspen Global Incorporated

Phase 3

24 5

Novantrone

Pfizer

Phase 3

8 6

Neupogen

EEastern Cooperative Oncology Group

Phase 3

15 7

Oncovin

EEastern Cooperative Oncology Group

Phase 3

15 8

Busulfex

Akero Therapeutics

Phase 3

13 9

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

12 10

Mesnex

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Leukemia

NCT03206671

Clinical

Trials by Indication[1]

Leukemia1 trial

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Active, not recruiting·UUniversity Hospital Muenster·Phase 3·NCT03206671·650 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vindesine Sulfate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vindesine Sulfate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vindesine Sulfate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital Muenster company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital Muenster

Vindesine Sulfate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Leukemia1 trial

References

Drug Info

Quick Facts

Related News